Vertex Pharma (VRTX) Renal Pipeline Seen as Major Growth Driver by Barclays

1 day ago 4

Sheryar Siddiq

Fri, February 13, 2026 astatine 8:54 AM CST 1 min read

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best precocious maturation precocious borderline stocks to bargain now. On January 28, Barclays began sum of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with an Overweight standing and a $606 terms target, voicing assurance astir Vertex’s renal franchise, implying that it mightiness execute important marketplace attraction successful 2026 and possibly travel the occurrence established by the company’s cystic fibrosis (CF) operation. The steadfast emphasized that Vertex’s CF therapies proceed to rake successful important currency flows, which could let for aboriginal commercialized development.

Barclays expects Vertex’s IgAN (immunoglobulin A nephropathy) programme to output encouraging results aboriginal this year, adding that the renal franchise’s prospects proceed to beryllium “underappreciated” by the market.

Barclays besides mentioned Journavx, claiming that the summation successful prescriptions and revenues successful 2026 has lately been “overlooked” by the market.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is simply a planetary biotechnology company. It develops and commercializes therapies for superior diseases, with a superior absorption connected cystic fibrosis and familial disorders.

While we admit the imaginable of VRTX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.

Read Entire Article